View Older Stories View More Recent Stories

Apr 23, 2026 04:05PM AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
Mar 30, 2026 08:01AM Allergan Aesthetics presents data on investigational neurotoxin at AAD
Mar 30, 2026 08:00AM Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology
Mar 26, 2026 05:45AM Allergan Aesthetics presents 21 research posters at Monaco medical congress
Mar 26, 2026 04:00AM Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)
Mar 26, 2026 03:00AM Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco
Mar 24, 2026 08:00AM AbbVie Named Official Pharmaceutical Partner of Major League Baseball
Mar 19, 2026 03:00AM Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions
Feb 3, 2026 08:50AM Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
Jan 28, 2026 08:00AM Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
Jan 16, 2026 01:43PM AbbVie reports mixed results for lymphoma drug in phase 3 trial
Jan 16, 2026 01:43PM AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Jan 12, 2026 06:35PM AbbVie (ABBV) and Trump Administration Reach Agreement To Cut Drug Prices, $100 bln Investment
Jan 12, 2026 06:30PM AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
Jan 12, 2026 07:30AM AbbVie licenses cancer drug from RemeGen for $650 million upfront
Jan 12, 2026 07:30AM AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
Jan 12, 2026 06:00AM AbbVie to acquire West Pharmaceutical facility in Arizona for $175M
Jan 12, 2026 06:00AM AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
Jan 7, 2026 08:00AM AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
Jan 5, 2026 08:00AM AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
Dec 2, 2025 08:15AM AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
Nov 24, 2025 08:00AM AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
Nov 18, 2025 12:48PM AbbVie receives FDA approval for EPKINLY combination therapy for lymphoma
Nov 18, 2025 12:47PM AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
Nov 14, 2025 12:30PM AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
Nov 13, 2025 08:30AM AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
Nov 12, 2025 08:30AM Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
Oct 31, 2025 07:49AM AbbVie Reports Third-Quarter 2025 Financial Results
Oct 29, 2025 05:00PM The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
Oct 29, 2025 08:11AM AbbVie's upadacitinib meets vitiligo study endpoints
Oct 29, 2025 08:11AM AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
Oct 28, 2025 09:00AM Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM
Oct 21, 2025 08:00AM The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
Oct 20, 2025 08:00AM AbbVie's RINVOQ outperforms HUMIRA in rheumatoid arthritis study
Oct 20, 2025 08:00AM RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
Oct 17, 2025 09:00AM AbbVie completes acquisition of Gilgamesh's depression drug bretisilocin
Oct 17, 2025 09:00AM AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
Oct 13, 2025 10:58AM FDA approves expanded RINVOQ indication for inflammatory bowel disease
Oct 13, 2025 10:57AM U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
Oct 13, 2025 07:15AM AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
Oct 9, 2025 08:00AM SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
Oct 6, 2025 09:02AM AbbVie's Botox meets primary endpoint in essential tremor trial
Oct 6, 2025 09:00AM AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
Oct 2, 2025 08:00AM AbbVie to Host Third-Quarter 2025 Earnings Conference Call
Sep 30, 2025 03:02PM AbbVie starts $70 million expansion at Massachusetts biologics facility
Sep 30, 2025 03:00PM AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
Sep 30, 2025 08:01AM AbbVie submits FDA application for rare blood cancer treatment
Sep 30, 2025 08:00AM AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
Sep 29, 2025 12:01PM AbbVie breaks ground on $195 million Illinois manufacturing facility
Sep 29, 2025 12:00PM AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
View More Recent Stories View Older Stories